Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3α,5α-tetrahydrodeoxycorticosterone concentrations

Psychoneuroendocrinology

Volumn 34, Issue 10, 2009, Pages 1586-1589

  Zwanzger, Peter ^a,b   Eser, Daniela ^a   Romeo, Elena ^c   di Michele, Flavia ^c   Baghai, Thomas C ^a   Pasini, Augusto ^c   Padberg, Frank ^a   Rupprecht, Rainer ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cholecystokinin tetrapeptide (CCK 4); Neuroactive steroids; Neurosteroids; Panic attacks; Tiagabine

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 3ALPHA,5ALPHA TETRAHYDRODEOXYCORTICOSTERONE; 4 AMINOBUTYRIC ACID; HYDROCORTISONE; NEUROSTEROID; PRASTERONE; PROGESTERONE; TETRAGASTRIN; TETRAHYDRODEOXYCORTICOSTERONE; TIAGABINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FEMALE; GABAERGIC SYSTEM; GAS CHROMATOGRAPHY; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PANIC; PILOT STUDY; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ADULT; DESOXYCORTICOSTERONE; FEMALE; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; NEUROTRANSMITTER UPTAKE INHIBITORS; NIPECOTIC ACIDS; PANIC DISORDER; PILOT PROJECTS; TETRAGASTRIN;

EID: 70349802309     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2009.04.017     Document Type: Article

References (15)

1. Brambilla F., Mellado C., Alciati A., Pisu M.G., Purdy R.H., Zanone S., Perini G., Serra M., and Bigio G. Plasma concentrations of anxiolytic neuroactive steroids in men with panic disorder. Psychiatry Res. 135 (2005) 185-190
2. Eser D., di Michele F., Zwanzger P., Pasini A., Baghai T.C., Schule C., Rupprecht R., and Romeo E. Panic induction with cholecystokinin-tetrapeptide (CCK-4) increases plasma concentrations of the neuroactive steroid 3alpha, 5alpha tetrahydrodeoxycorticosterone (3alpha, 5alpha-THDOC) in healthy volunteers. Neuropsychopharmacology 30 (2005) 192-195
3. Eser D., Schüle C., Baghai T., Floesser A., Krebs-Brown A., Enunwa M., De la Motte S., Engel R., Kucher K., and Rupprecht R. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology 192 (2007) 479-487
4. Goddard A.W., Mason G.F., Almai A., Rothman D.L., Behar K.L., Petroff O.A., Charney D.S., and Krystal J.H. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch. Gen. Psychiatry 58 (2001) 556-561
5. Hasler G., Nugent A.C., Carlson P.J., Carson R.E., Geraci M., and Drevets W.C. Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch. Gen. Psychiatry 65 (2008) 1166-1175
6. Koszycki D., Zacharko R.M., Le Melledo J.M., and Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depress. Anxiety 8 (1998) 1-7
7. Purdy R.H., Morrow A.L., Moore P.H., and Paul S.M. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 4553-4557
8. Rogawski M.A., and Reddy D.S. Neurosteroids and infantile spasms: the deoxycorticosterone hypothesis. Int. Rev. Neurobiol. 49 (2002) 199-219
9. Romeo E., Strohle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., and Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry 155 (1998) 910-913
10. Rupprecht R., and Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci. 22 (1999) 410-416
11. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur. J. Endocrinol. 145 (2001) 669-679
12. Strohle A., Romeo E., di Michele F., Pasini A., Yassouridis A., Holsboer F., and Rupprecht R. GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am. J. Psychiatry 159 (2002) 145-147
13. Uzunov D.P., Cooper T.B., Costa E., and Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 12599-12604
14. Zwanzger P., Baghai T.C., Schule C., Minov C., Padberg F., Moller H.J., and Rupprecht R. Tiagabine improves panic and agoraphobia in panic disorder patients. J. Clin. Psychiatry 62 (1999) 656-657
15. Zwanzger P., Eser D., Padberg F., Baghai T.C., Schule C., Rotzer F., Ella R., Moller H.J., and Rupprecht R. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress. Anxiety 18 (2003) 140-143